http://orcid.org/0000-0003-2469-5954
References
- Boulanger J, Ducharme A, Dufour A, et al. Management of the extravasation of anti-neoplastic agents. Support Care Cancer. 2015;23(5):1459–1471.
- Pluschnig U, Haslik W, Bartsch R, Mader RM. Extravasation emergencies: state-of-the-art management and progress in clinical research. Memo. 2016;9(4):226–230.
- Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15(6):858–862.
- Sauerland C, Engelking C, Wickham R, et al. Vesicant extravasation part I: mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum. 2006;33(6):1134–1141.
- Bertelli G, Dini D, Forno GB, et al. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol. 1994;120(8):505–506.
- Schneider SM, Distelhorst CW. Chemotherapy-induced emergencies. Semin Oncol. 1989;16(6):572–578.
- Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf. 1995;12(4):245–255.
- Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst. 1985;74(1):113–120.
- Shapiro J, Richardson GE, Paclitaxel-induced “recall” soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. J Clin Oncol. 1994;121. (10):2237–2238.
- Jacob SW, Bischel M, Herschler RJ. Dimethylsulfoxide: a new concept in pharmacotherapy. Curr Ther Res Clin Exp. 1964;6:134–135.
- Grissinger M. Death and neurological devastation from intrathecal vinca alkaloids. P T. 2016;41(8):464–525.